Headlines about Rockwell Medical (NASDAQ:RMTI) have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rockwell Medical earned a news impact score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.807971484909 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern’s analysis:

Several equities research analysts have issued reports on RMTI shares. ValuEngine downgraded Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Ifs Securities started coverage on Rockwell Medical in a report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price objective on the stock. Three analysts have rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.38.

Shares of Rockwell Medical (NASDAQ:RMTI) traded up 3.11% on Monday, hitting $6.63. The stock had a trading volume of 188,915 shares. The firm’s 50-day moving average is $6.50 and its 200 day moving average is $6.98. Rockwell Medical has a 1-year low of $3.55 and a 1-year high of $8.98. The stock’s market cap is $343.04 million.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The firm had revenue of $13.24 million during the quarter, compared to analyst estimates of $13.05 million. Rockwell Medical had a negative net margin of 39.68% and a negative return on equity of 42.22%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the company earned ($0.11) EPS. Equities analysts forecast that Rockwell Medical will post ($0.44) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Rockwell Medical (RMTI) Earning Somewhat Positive Press Coverage, Report Finds” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/rockwell-medical-rmti-earning-somewhat-positive-press-coverage-report-finds.html.

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Insider Buying and Selling by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Stock Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related stocks with our FREE daily email newsletter.